A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

@article{Oettle2005API,
  title={A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.},
  author={Helmut Oettle and Donald Richards and Ramesh K. Ramanathan and Jean-Luc van Laethem and Marc Peeters and Martin R. Fuchs and Annamaria Zimmermann and William John and Daniel von Hoff and Michael B Arning and Hedy Lee Kindler},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2005},
  volume={16 10},
  pages={1639-45}
}
BACKGROUND This randomized phase III study compared the overall survival (OS) of pemetrexed plus gemcitabine (PG) versus standard gemcitabine (G) in patients with advanced pancreatic cancer. PATIENTS AND METHODS Patients with unresectable locally advanced or metastatic pancreatic cancer and no prior systemic therapy (including 5-fluorouracil as a radiosensitizer) were randomized to receive either 1,250 mg/m(2) gemcitabine on days 1 and 8 plus pemetrexed 500 mg/m(2) after gemcitabine on day 8… CONTINUE READING